Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CAD 215.95 billion. The enterprise value is 233.47 billion.

Market Cap	215.95B
Enterprise Value	233.47B

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	Mar 13, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.87%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.51 and the forward PE ratio is 14.86.

PE Ratio	18.51
Forward PE	14.86
PS Ratio	5.35
PB Ratio	6.96
P/TBV Ratio	n/a
P/FCF Ratio	16.66
P/OCF Ratio	15.72
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.63, with an EV/FCF ratio of 18.01.

EV / Earnings	20.01
EV / Sales	5.82
EV / EBITDA	11.63
EV / EBIT	14.51
EV / FCF	18.01

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.37M
Profits Per Employee	686,367
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 1.76 billion in taxes.

Income Tax	1.76B
Effective Tax Rate	13.13%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	29.28
200-Day Moving Average	25.63
Relative Strength Index (RSI)	29.00
Average Volume (20 Days)	2,040

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.45

Income Statement

In the last 12 months, Gilead Sciences had revenue of CAD 40.37 billion and earned 11.67 billion in profits. Earnings per share was 9.30.

Revenue	40.37B
Gross Profit	31.83B
Operating Income	16.20B
Pretax Income	13.43B
Net Income	11.67B
EBITDA	19.99B
EBIT	16.20B
Earnings Per Share (EPS)	9.30

Balance Sheet

The company has 13.18 billion in cash and 35.02 billion in debt, giving a net cash position of -17.76 billion.

Cash & Cash Equivalents	13.18B
Total Debt	35.02B
Net Cash	-17.76B
Net Cash Per Share	n/a
Equity (Book Value)	31.01B
Book Value Per Share	25.08
Working Capital	8.95B

Cash Flow

In the last 12 months, operating cash flow was 13.74 billion and capital expenditures -771.94 million, giving a free cash flow of 12.97 billion.

Operating Cash Flow	13.74B
Capital Expenditures	-771.94M
Depreciation & Amortization	3.77B
Net Borrowing	-2.45B
Free Cash Flow	12.97B
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 0.66, which amounts to a dividend yield of 2.51%.

Dividend Per Share	0.66
Dividend Yield	2.51%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	47.04%
Buyback Yield	0.24%
Shareholder Yield	2.75%
Earnings Yield	5.40%
FCF Yield	6.00%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7